Topic summary

Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1

Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial cagrilintide

This is a generated summary. It shows the 5 most-liked posts from a topic of 32, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

i.dumitruTL2 Moderator15 Jul 2025#1

On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion.

I have seen SELECT (N Engl J Med, 2023) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows.

My reading is that the trial is sound for its own question and is being stretched to answer a different one. I might be wrong about that, which is why this is a topic rather than a correction.

What I would like from this discussion: someone who disagrees with me to say why, with the section of the paper they are relying on.

48 likes 12mo

KStephanopoulosTL3Regular19 Jul 2025#13

i.dumitru, post #1: On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows. My reading is that the trial is… Go to post

I read post #11 twice before replying, because I had assumed the opposite.

Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.

24 likes in reply to #1 12mo

n.serranoTL2 Moderator20 Jul 2025#21

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

30 likes 12mo

s.poulsenTL3Regular22 Jul 2025#30

Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years.

31 likes 12mo

m.restrepoTL2 Moderator22 Jul 2025#31

j.nascimento, post #7: Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer. Go to post

21 likes in reply to #7 12mo

Read the full topic (32 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Second pass at: Reading a combination trial: attributing effect to components Compounds › Cagrilintide & amylin analogues cagrilintide randomised trial amylin analogues effect size Second pass at: Reading a combination trial: attributing effect to components — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in support of…	+39	43	7.3k	12mo
Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial Wiki On the subject in the title: Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please…	+2	6	2.4k	7mo
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Compounds › Cagrilintide & amylin analogues effect size cagrilintide cagrisema amylin analogues Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with FLOW ( N Engl…	+48	53	31k	13mo
Why cagrilintide alone is discussed so much less than in combination — does this still hold? Compounds › Cagrilintide & amylin analogues cagrisema randomised trial cagrilintide effect size Solved Under review Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4…	+27	31	1.2k	22h
Reading a combination trial: attributing effect to components Compounds › Cagrilintide & amylin analogues cagrisema amylin analogues effect size cagrilintide Closed On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…		4	19k	11mo

Related topics — sharing the tags cagrisema, effect size, randomised trial

Topic	Participants	Replies	Views	Activity
The C-cell question: rodent findings and their human context — what changed since Compounds › Semaglutide effect size SELECT trial randomised trial type 2 diabetes Closed The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support…	+61	65	1.3k	22mo
Measurement error in a self-reported exposure Evidence › Study critique confounding risk of bias effect size disputed Solved Closed Posting this under the heading it deserves: Measurement error in a self-reported exposure Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it before…	+117	129	45k	5mo
A claim built entirely on a subgroup analysis — what changed since Evidence › Study critique disputed effect size observational data risk of bias Closed On the subject in the title: A claim built entirely on a subgroup analysis — what changed since Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…		2	2k	18mo
Second pass at: Semaglutide and alcohol: what is actually documented Compounds › Semaglutide semaglutide type 2 diabetes effect size randomised trial Closed Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…	+15	19	4.4k	13mo
Retatrutide's phase 2 heart-rate signal and how to think about it Compounds › Retatrutide randomised trial preprint TRIUMPH programme retatrutide On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…	+19	23	20k	7mo